Your browser doesn't support javascript.
loading
Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.
Tamburro, Robert F; Cooke, Kenneth R; Davies, Stella M; Goldfarb, Samuel; Hagood, James S; Srinivasan, Ashok; Steiner, Marie E; Stokes, Dennis; DiFronzo, Nancy; El-Kassar, Nahed; Shelburne, Nonniekaye; Natarajan, Aruna.
Afiliação
  • Tamburro RF; Eunice Kennedy Shriver National Institutes of Child Health and Human Development, Bethesda, Maryland.
  • Cooke KR; Department of Oncology, Pediatric Blood and Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
  • Davies SM; Department of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Goldfarb S; Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Hagood JS; Pediatric Pulmonology and Program for Rare and Interstitial Lung Disease, University of North Carolina, Chapel Hill, North Carolina.
  • Srinivasan A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Steiner ME; University of Minnesota Academic Health Center, Minneapolis, Minnesota.
  • Stokes D; Department of Pediatrics (Pulmonology), University of Tennessee College of Medicine, Memphis, Tennessee.
  • DiFronzo N; Pulmonology Division, Le Bonheur Children's Hospital, Memphis, Tennessee.
  • El-Kassar N; National Heart, Lung, Blood Institute, Bethesda, Maryland; and.
  • Shelburne N; National Heart, Lung, Blood Institute, Bethesda, Maryland; and.
  • Natarajan A; National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ann Am Thorac Soc ; 18(3): 381-394, 2021 03.
Article em En | MEDLINE | ID: mdl-33058742
ABSTRACT
Approximately 2,500 pediatric hematopoietic cell transplants (HCTs), most of which are allogeneic, are performed annually in the United States for life-threatening malignant and nonmalignant conditions. Although HCT is undertaken with curative intent, post-HCT complications limit successful outcomes, with pulmonary dysfunction representing the leading cause of nonrelapse mortality. To better understand, predict, prevent, and/or treat pulmonary complications after HCT, a multidisciplinary group of 33 experts met in a 2-day National Institutes of Health Workshop to identify knowledge gaps and research strategies most likely to improve outcomes. This summary of Workshop deliberations outlines the consensus focus areas for future research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies Limite: Child / Humans País/Região como assunto: America do norte Idioma: En Revista: Ann Am Thorac Soc Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies Limite: Child / Humans País/Região como assunto: America do norte Idioma: En Revista: Ann Am Thorac Soc Ano de publicação: 2021 Tipo de documento: Article